Transcriptomics

Dataset Information

0

Expression data from LNCaP cells treated with DHT and enzalutamide


ABSTRACT: Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: (1) binding of androgens to AR, (2) AR nuclear translocation, and (3) association of AR with DNA. Here we used Affymetrix human genome microarray technology to investigate the global programme of gene expression of LNCaP cells in response to enzalutamide alone and in the context of DHT-stimulated androgen receptor gene expression.

ORGANISM(S): Homo sapiens

PROVIDER: GSE44905 | GEO | 2013/04/01

SECONDARY ACCESSION(S): PRJNA192516

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-04-01 | E-GEOD-44905 | biostudies-arrayexpress
2016-06-10 | E-GEOD-69896 | biostudies-arrayexpress
2015-03-02 | E-GEOD-60841 | biostudies-arrayexpress
2014-04-25 | E-GEOD-55063 | biostudies-arrayexpress
2016-06-10 | GSE69896 | GEO
2014-04-25 | E-GEOD-55062 | biostudies-arrayexpress
2016-06-30 | E-GEOD-61630 | biostudies-arrayexpress
2014-04-25 | GSE55062 | GEO
2014-04-25 | GSE55063 | GEO
2015-03-02 | GSE60841 | GEO